Portfolio

Aisling Capital invests in products, technologies and businesses that advance health.
In addition to investing in companies developing pharmaceutical, biotechnology and medical products, Aisling invests in businesses that provide drug development, manufacturing and other important services to the healthcare industry.

Aclaris Therapeutics, Inc.

NasdaqGS: ACRS

Specialty pharmaceutical company, focusing on identifying, developing, and commercializing topical drugs to address various needs in dermatology.
- Year Invested
  2016
- Fund
  IV
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  Malvern, PA
- Website
  aclaristx.com
Adams Respiratory Therapeutics, Inc.

Specialty pharmaceutical company engaged in the development, commercialization and marketing of over-the-counter and prescription drugs for the treatment of respiratory disorders
- Year Invested
  2001
- Fund
  I
- Sector
  Consumer
- Company Status
  acquired
- Investment Status
  historic
- Location
  Chester, NJ
- Website
  rb.com
ADMA Biologics, Inc.

NasdaqCM:ADMA

Biopharmaceutical company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of infectious diseases
- Year Invested
  2007
- Fund
  II
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  Ramsey, NJ
- Website
  admabiologics.com
Advion, Inc.

Provider of bioanalytical testing equipment to the pharmaceutical industry
- Year Invested
  2002
- Fund
  I
- Sector
  Services
- Company Status
  private
- Investment Status
  historic
- Location
  Ithaca, NY
- Website
  advion.com
Agile Therapeutics, Inc.

NasdaqGM:AGRX

Women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products
- Year Invested
  2012
- Fund
  III
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  Princeton, NJ
- Website
  agiletherapeutics.com
Aimmune Therapeutics, Inc.

NasdaqGS:AIMT

Biopharmaceutical company developing desensitization treatments for food allergies
- Year Invested
  2015
- Fund
  III
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  Brisbane, CA
- Website
  aimmune.com
Ajax Health

Medical device platform building a diversified portfolio of emerging medical device companies
- Year Invested
  2017
- Fund
  IV
- Sector
  Medical Device
- Company Status
  private
- Investment Status
  current
- Location
  Menlo Park, CA
- Website
  NA
Allos Therapeutics, Inc.

Biopharmaceutical company engaged in the development and commercialization of anti-cancer therapeutics
- Year Invested
  2002
- Fund
  I
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  Westminster, CO
- Website
  sppirx.com
Ambit Biosciences Corporation

Biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat oncology, autoimmune and inflammatory diseases
- Year Invested
  2001
- Fund
  I
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  San Diego, CA
- Website
  ambitbio.com
Aragon Pharmaceuticals, Inc.

Oncology drug development company focused on novel therapeutics for prostate and breast cancer
- Year Invested
  2010
- Fund
  III
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  New Brunswick, NJ
- Website
  jnj.com
Archimica Cooperatief U.A.

Manufacturer of active pharmaceutical ingredients and late state intermediates for the pharmaceutical industry
- Year Invested
  2006
- Fund
  II
- Sector
  Services
- Company Status
  acquired
- Investment Status
  historic
- Location
  Amsterdam, Netherlands
- Website
  euticals.com
Arcus Biosciences, Inc.

Biotechnology company developing cancer immunotherapies targeting the adenosine and other oncology pathways
- Year Invested
  2017
- Fund
  IV
- Sector
  Biopharma
- Company Status
  private
- Investment Status
  current
- Location
  Hayward, CA
- Website
  arcusbio.com
ARMGO Pharma, Inc.

Biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular and neurological disorders
- Year Invested
  2006
- Fund
  II
- Sector
  Biopharma
- Company Status
  private
- Investment Status
  current
- Location
  Tarrytown, NY
- Website
  armgo.com
ARMO BioSciences, Inc.

NasdaqGS:ARMO

Biotechnology company developing immuno-oncology therapies in combination with standard of care or emerging immunotherapies
- Year Invested
  2018
- Fund
  IV
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  Redwood City, CA
- Website
  armobio.com
Ascendis Pharma A/S

NasdaqGS:ASND

Endocrine-focused biopharmaceutical company developing long-acting human growth hormone for the treatment of pediatric growth hormone deficiency
- Year Invested
  2016
- Fund
  IV
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  Hellerup, Denmark
- Website
  ascendispharma.com
Aton Pharma, Inc.

Biotechnology company focused on the development of novel treatments for cancer
- Year Invested
  2002
- Fund
  I
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  Tarrytown, NY
- Website
  merck.com
Audentes Therapeutics, Inc.

NasdaqGM:BOLD

Biotechnology company developing gene therapy-based treatments in several serious, rare diseases
- Year Invested
  2017
- Fund
  IV
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  San Francisco, CA
- Website
  audentestx.com
Auxilium Pharmaceuticals, Inc.

NasdaqGS:AUXL

Specialty pharmaceutical company that develops and markets pharmaceutical products for urology and sexual health
- Year Invested
  2003
- Fund
  I
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  Chesterbrook, PA
- Website
  auxilium.com
AVANZA Laboratories, LLC

Contract research organization that provides GLP complaint drug development services for biotechnology and pharmaceutical firms, and government agencies
- Year Invested
  2009
- Fund
  II
- Sector
  Services
- Company Status
  acquired
- Investment Status
  historic
- Location
  Gaithersburg, MD
- Website
  smithersavanza.com
AVROBIO, Inc.

Biotechnology company developing gene therapies to treat rare diseases, specifically lysosomal storage disorders (LSDs)
- Year Invested
  2018
- Fund
  IV
- Sector
  Biopharma
- Company Status
  private
- Investment Status
  current
- Location
  Cambridge, MA
- Website
  avrobio.com
Axcan Pharma, Inc.

Specialty pharmaceutical company focused on the treatment of gastrointestinal disorders
- Year Invested
  2000
- Fund
  I
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  Quebec, Canada
- Website
  actavis.com
Barrier Therapeutics, Inc.

Specialty pharmaceutical company focused on development and commercialization of dermatology drugs
- Year Invested
  2002
- Fund
  I
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  Princeton, NJ
- Website
  stiefel.com
Bioenvision, Inc.

Biotechnology company focused on the development and commercialization of drugs to treat oncology and infectious disease
- Year Invested
  2002
- Fund
  I
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  New York, NY
- Website
  genzyme.com
Biohaven Pharmaceuticals Ltd.

NYSE:BHVN

Biopharmaceutical company developing treatments for orphan neurologic indications and other areas of large unmet medical needs
- Year Invested
  2016
- Fund
  IV
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  New Haven, CT
- Website
  biohavenpharma.com
BridgeBio Pharma LLC

Orphan disease drug platform with a robust portfolio of transformative drug programs that address rare diseases across oncology, cardiology, dermatology, neurology and endocrinology
- Year Invested
  2017
- Fund
  IV
- Sector
  Biopharma
- Company Status
  private
- Investment Status
  current
- Location
  Palo Alto, CA
- Website
  bridgebio.com
Cardiokine, Inc.

Biotechnology company developing drugs for the treatment and prevention of cardiovascular diseases
- Year Invested
  2004
- Fund
  I
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  Philadelphia, PA
- Website
  chiesiusa.com
Catalent, Inc.

NYSE:CTLT

Provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products
- Year Invested
  2007
- Fund
  II
- Sector
  Services
- Company Status
  public
- Investment Status
  historic
- Location
  Somerset, NJ
- Website
  catalent.com
Cempra, Inc.

NasdaqGS:CEMP

Drug discovery and development company focused on infectious diseases and the treatment of drug-resistant bacteria
- Year Invested
  2006
- Fund
  II
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  Chapel Hill, NC
- Website
  cempra.com
Chimerix, Inc.

NasdaqGM:CMRX

Biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need
- Year Invested
  2013
- Fund
  III
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  Durham, NC
- Website
  chimerix.com
Cidara Therapeutics, Inc.

NasdaqGM:CDTX

Drug discovery and development company focused on devastating fungal infections that often complicate cancer and transplant treatments
- Year Invested
  2008
- Fund
  II
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  San Diego, CA
- Website
  cidara.com
Clovis Oncology, Inc.

NasdaqGS:CLVS

Biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents
- Year Invested
  2011
- Fund
  III
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  Boulder, CO
- Website
  clovisoncology.com
CollaGenex Pharmaceuticals, Inc.

Specialty pharmaceutical company that develops and markets proprietary medical therapies to the dermatology market
- Year Invested
  2001
- Fund
  I
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  Newton, PA
- Website
  galderma.com
Colorescience, Inc.

Cosmetics company that manufactures and sells mineral-based products
- Year Invested
  2012
- Fund
  I
- Sector
  Consumer
- Company Status
  acquired
- Investment Status
  historic
- Location
  Carlsbad, CA
- Website
  colorescience.com
Cynapsus Therapeutics Inc.

NasdaqGM:CYNA

Specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease
- Year Invested
  2015
- Fund
  III
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  Toronto, Canada
- Website
  cynapsus.ca
Cytos Biotechnology AG

SWX:CYTN

Biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform
- Year Invested
  2012
- Fund
  III
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  Schlieren, Switzerland
- Website
  cytos.com
Dermira, Inc.

NasdaqGS:DERM

Specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients
- Year Invested
  2014
- Fund
  III
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  Redwood City, CA
- Website
  dermira.com
Durata Therapeutics, Inc.

Pharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions for physicians and providers to advance patient care in infectious disease and acute illnesses
- Year Invested
  2009
- Fund
  III
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  Chicago, IL
- Website
  duratatherapeutics.com
EarLens Corporation

Medical device company committed to providing hearing impaired patients a hearing solution that is designed to change the current standard of care for sound performance.
- Year Invested
  2014
- Fund
  III
- Sector
  Medical Device
- Company Status
  private
- Investment Status
  current
- Location
  Menlo Park, CA
- Website
  earlenscorp.com
Eidos Therapeutics

Biopharmaceutical company focused on addressing the unmet need in diseases caused by transthyretin amyloidosis (ATTR)
- Year Invested
  2018
- Fund
  IV
- Sector
  Biopharma
- Company Status
  private
- Investment Status
  current
- Location
  San Francisco, CA
- Website
  eidostx.com
Esperion Therapeutics, Inc.

NasdaqGM:ESPR

Drug discovery and development company focused on therapies that prevent, treat and reverse cardiovascular and metabolic diseases
- Year Invested
  2008
- Fund
  II
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  Ann Arbor, MI
- Website
  esperion.com
F2G Limited

Antifungal drug discovery and development company focused on novel therapies to treat life threatening invasive fungal infections
- Year Invested
  2016
- Fund
  IV
- Sector
  Biopharma
- Company Status
  private
- Investment Status
  current
- Location
  Manchester, UK
- Website
  f2g.com
Global Blood Therapeutics, Inc.

NasdaqGS:GBT

Biopharmaceutical company developing novel therapies to improve the lives of patients with serious blood-based disorders
- Year Invested
  2016
- Fund
  IV
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  South San Francisco, CA
- Website
  globalbloodtx.com
GTx, Inc.

NasdaqCM:GTXI

Biopharmaceutical company targeting hormone pathways to treat stress urinary incontinence (SUI) in women
- Year Invested
  2017
- Fund
  IV
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  Memphis, TN
- Website
  gtxinc.com
Harmony Biosciences, LLC

Biopharmaceutical company developing and commercializing innovative drugs to address unmet needs for patients with sleep and CNS disorders
- Year Invested
  2018
- Fund
  IV
- Sector
  Biopharma
- Company Status
  private
- Investment Status
  current
- Location
  Plymouth Meeting, PA
- Website
  harmonybiosciences.com
Ibrutinib Royalty

Anti-cancer drug targeting B-cell malignancies
- Year Invested
  2013
- Fund
  III
- Sector
  Biopharma
- Company Status
  private
- Investment Status
  historic
- Location
  N/A
- Website
  imbruvica.com
Infinity Pharmaceuticals, Inc.

NasdaqGS:INFI

Biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to patients with difficult-to-treat diseases
- Year Invested
  2012
- Fund
  III
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  Cambridge, MA
- Website
  infi.com
Intercept Pharmaceuticals, Inc.

NasdaqGS:ICPT

Biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing our proprietary bile acid chemistry
- Year Invested
  2012
- Fund
  III
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  New York, NY
- Website
  interceptpharma.com
Intersect ENT, Inc.

NasdaqGM:XENT

Commercial stage drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions
- Year Invested
  2014
- Fund
  III
- Sector
  Medical Device
- Company Status
  public
- Investment Status
  historic
- Location
  Menlo Park, CA
- Website
  propelopens.com
LENSAR, Inc.

Leader in next-generation femtosecond laser technology for refractive cataract surgery
- Year Invested
  2008
- Fund
  II
- Sector
  Medical Device
- Company Status
  private
- Investment Status
  historic
- Location
  Orlando, FL
- Website
  lensar.com
Lombard Medical, Inc.

NasdaqGM:EVAR

Medical technology company specializing in developing, manufacturing and marketing endovascular stent-grafts that address significant unmet needs in the repair of aortic aneurysms
- Year Invested
  2014
- Fund
  III
- Sector
  Medical Device
- Company Status
  public
- Investment Status
  historic
- Location
  Oxfordshire, UK
- Website
  lombardmedical.com
Loxo Oncology, Inc.

NasdaqGM:LOXO

Biotechnology company developing targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations
- Year Invested
  2013
- Fund
  III
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  Stamford, CT
- Website
  loxooncology.com
MAP Pharmaceuticals, Inc.

Specialty pharmaceutical company developing new therapies based on proprietary drug particle and inhalation technologies
- Year Invested
  2003
- Fund
  I
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  Mountain View, CA
- Website
  allergan.com
MEI Pharma, Inc.

NasdaqCM:MEIP

Oncology company focused on the clinical development of novel therapies for cancer
- Year Invested
  2013
- Fund
  III
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  San Diego, CA
- Website
  meipharma.com
Menlo Therapeutics Inc.

Biopharmaceutical company developing an oral therapy for the treatment of chronic pruritus associated with various conditions and chronic cough
- Year Invested
  2017
- Fund
  IV
- Sector
  Biopharma
- Company Status
  private
- Investment Status
  current
- Location
  Menlo Park, CA
- Website
  menlotherapeutics.com
Miramar Labs, Inc.

OTC:MRLB

Medical device company focused on developing products for dermatologic medical conditions
- Year Invested
  2011
- Fund
  III
- Sector
  Medical Device
- Company Status
  acquired
- Investment Status
  historic
- Location
  Sunnyvale, CA
- Website
  miradry.com
Myogen, Inc.

Biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders
- Year Invested
  2001
- Fund
  I
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  Westminster, CO
- Website
  gilead.com
NextWave Pharmaceuticals, Inc.

Specialty pharmaceutical company developing extended release OTC and prescription products for children and adults
- Year Invested
  2007
- Fund
  II
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  Cupertino, CA
- Website
  pfizer.com
Novazyme Pharmaceuticals, Inc.

Biotechnology company focused on drugs to treat lysosomal storage diseases
- Year Invested
  2000
- Fund
  I
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  Princeton, NJ
- Website
  genzyme.com
ObsEva SA

NasdaqGS:OBSV

Biopharmaceutical company developing novel therapeutics in women's health for the treatment of symptoms associated with endometriosis and uterine fibroids
- Year Invested
  2017
- Fund
  IV
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  Geneva, Switzerland
- Website
  obseva.com
Oculex Pharmaceuticals, Inc.

Ophthalmic drug delivery company with platform technology to facilitate the treatment of major sight-threatening eye diseases and conditions
- Year Invested
  2002
- Fund
  I
- Sector
  Medical Device
- Company Status
  acquired
- Investment Status
  historic
- Location
  Sunnyvale, CA
- Website
  allergan.com
Paratek Pharmaceuticals, Inc.

NasdaqGM:PRTK

Biopharmaceutical company engaged in the discovery, development and commercialization of antibiotics to save lives and alleviate suffering
- Year Invested
  2007
- Fund
  II
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  Boston, MA
- Website
  paratekpharm.com
Pernix Therapeutics, Inc.

NasdaqGM:PTX

Specialty pharmaceutical company primarily focused on the sales, marketing and development of branded pharmaceutical products
- Year Invested
  2011
- Fund
  III
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  Houston, TX
- Website
  pernixtx.com
Pharmaron, Inc.

Provider of research and development services for pharmaceutical and biotechnological industries worldwide
- Year Invested
  2006
- Fund
  II
- Sector
  Services
- Company Status
  private
- Investment Status
  historic
- Location
  Beijing, China
- Website
  pharmaron.com
Planet Biopharmaceuticals, Inc.

Developer and manufacturer of allergenic extracts and other products for the treatment and prevention of allergy
- Year Invested
  2007
- Fund
  II
- Sector
  Consumer
- Company Status
  acquired
- Investment Status
  historic
- Location
  Liberty, MO
- Website
  areslifesciences.com
PowerVision, Inc.

Developer of a fluid-controlled intraocular lens
- Year Invested
  2014
- Fund
  III
- Sector
  Medical Device
- Company Status
  private
- Investment Status
  current
- Location
  Belmont, CA
- Website
  powevisionlens.com
PreCision Dermatology, Inc.

Specialty pharmaceutical company developing, manufacturing and marketing prescription and consumer dermatology products
- Year Invested
  2012
- Fund
  III
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  Cumberland, RI
- Website
  valeant.com
Prolacta Bioscience, Inc.

Biopharmaceutical company developing and marketing human milk-based nutritional products for premature infants in the neonatal intensive care unit
- Year Invested
  2016
- Fund
  IV
- Sector
  Biopharma
- Company Status
  private
- Investment Status
  current
- Location
  City of Industry, CA
- Website
  prolacta.com
Promentis Pharmaceuticals, Inc.

Biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders of System XC-
- Year Invested
  2016
- Fund
  IV
- Sector
  Biopharma
- Company Status
  private
- Investment Status
  current
- Location
  Milwaukee, WI
- Website
  promentispharma.com
Protagonist Therapeutics, Inc.

NasdaqGM: PTGX

Clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs in inflammatory bowel diseases
- Year Invested
  2016
- Fund
  IV
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  Milpitas, CA
- Website
  protagonist-inc.com
Quintiles Transnational Holdings Inc.

NYSE:Q

Contract pharmaceutical research and sales organization
- Year Invested
  2003
- Fund
  I
- Sector
  Services
- Company Status
  public
- Investment Status
  historic
- Location
  Durham, NC
- Website
  quintiles.com
Roka Bioscience, Inc.

NasdaqGM:ROKA

Molecular diagnostics company focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens
- Year Invested
  2011
- Fund
  III
- Sector
  Diagnostics
- Company Status
  public
- Investment Status
  historic
- Location
  Warren, NJ
- Website
  rokabio.com
Seragon Pharmaceuticals, Inc.

Biopharmaceutical company focused on developing drugs for the treatment of estrogen receptor dependent breast cancer
- Year Invested
  2013
- Fund
  III
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  San Diego, CA
- Website
  gene.com
Sirion Therapeutics, Inc.

Ophthalmic-focused biopharmaceutical company engaged in the discovery, development and commercialization of products for the protection and preservation of eyesight
- Year Invested
  2007
- Fund
  II
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  Tampa, FL
- Website
  N/A
SkinMedica, Inc.

Specialty pharmaceutical company focused on development and commercialization of dermatology drugs and cosmeceuticals
- Year Invested
  2004
- Fund
  I
- Sector
  Consumer
- Company Status
  acquired
- Investment Status
  historic
- Location
  Carlsbad, CA
- Website
  skinmedica.com
Sorrento Therapeutics, Inc.

NasdaqCM:SRNE

Biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs
- Year Invested
  2013
- Fund
  III
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  San Diego, CA
- Website
  sorrentotherapeutics.com
Spirox, Inc.

Medical device company that is focused on developing minimally invasive technologies that improve the quality of life for patients with nasal obstruction
- Year Invested
  2015
- Fund
  III
- Sector
  Medical Device
- Company Status
  acquired
- Investment Status
  historic
- Location
  Menlo Park, CA
- Website
  spiroxmed.com
Sunesis Pharmaceuticals, Inc.

NasdaqCM:SNSS

Biopharmaceutical company developing oncology therapeutics for the treatment of solid and hematologic cancers
- Year Invested
  2016
- Fund
  IV
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  San Francisco, CA
- Website
  sunesis.com
Synergy Pharmaceuticals Inc.

NasdaqGS:SGYP

Biopharmaceutical company focused on the development of novel therapies based on the natural human hormone, uroguanylin, to treat gastrointestinal (GI) diseases and disorders
- Year Invested
  2014
- Fund
  III
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  New York, NY
- Website
  synergypharma.com
Syros Pharmaceuticals, Inc.

NasdaqGS:SYRS

Life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases
- Year Invested
  2014
- Fund
  III
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  Watertown, MA
- Website
  syros.com
T2 Biosystems, Inc.

NasdaqGM:TTOO

In vitro diagnostics company that has developed a technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies
- Year Invested
  2011
- Fund
  III
- Sector
  Diagnostics
- Company Status
  public
- Investment Status
  historic
- Location
  Lexington, MA
- Website
  t2biosystems.com
Topaz Pharmaceuticals, Inc.

Specialty pharmaceutical company focused on developing and commercializing treatments primarily for the pediatric and dermatology markets.
- Year Invested
  2007
- Fund
  II
- Sector
  Biopharma
- Company Status
  acquired
- Investment Status
  historic
- Location
  Horsham, PA
- Website
  sanofi.us
TransEnterix, Inc.

NYSEMKT:TRXC

Medical device company that is focused on the development and commercialization of manual and robotic assisted surgical systems for minimally invasive surgery
- Year Invested
  2009
- Fund
  III
- Sector
  Medical Device
- Company Status
  public
- Investment Status
  current
- Location
  Morrisville, NC
- Website
  transenterix.com
TRIA Beauty, Inc.

Medical device company developing and commercializing at-home, light-based skincare products
- Year Invested
  2008
- Fund
  II
- Sector
  Consumer
- Company Status
  private
- Investment Status
  historic
- Location
  Dublin, CA
- Website
  triabeauty.com
Verona Pharma plc

NasdaqGM:VRNA

UK-based biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant medical unmet needs
- Year Invested
  2016
- Fund
  IV
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  London, UK
- Website
  veronapharma.com
Versartis, Inc.

NasdaqGS:VSAR

Endocrine-focused biopharmaceutical company developing novel long-acting recombinant human growth hormone for growth hormone deficiency
- Year Invested
  2013
- Fund
  III
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  Redwood City, CA
- Website
  versartis.com
ViewRay, Inc.

OTCQB: VRAY

Medical device company developing advanced radiation therapy technology for the treatment of cancer
- Year Invested
  2008
- Fund
  II
- Sector
  Medical Device
- Company Status
  public
- Investment Status
  current
- Location
  Oakwood Village, OH
- Website
  viewray.com
VIVUS, Inc.

NasdaqGS:VVUS

Biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health
- Year Invested
  2006
- Fund
  II
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  historic
- Location
  Mountain View, CA
- Website
  vivus.com
Zavante Therapeutics, Inc.

Biopharmaceutical company focused on novel products that address serious unmet medical needs in the hospital
- Year Invested
  2016
- Fund
  IV
- Sector
  Biopharma
- Company Status
  private
- Investment Status
  current
- Location
  San Diego
- Website
  zavante.com
ZELTIQ Aesthetics, Inc.

NasdaqGS:ZLTQ

Medical technology company focused on developing and commercializing products utilizing a controlled cooling technology platform for non-invasive fat reduction
- Year Invested
  2010
- Fund
  III
- Sector
  Consumer
- Company Status
  acquired
- Investment Status
  historic
- Location
  Pleasanton, CA
- Website
  coolsculpting.com
Zosano Pharma Corporation

NasdaqCM:ZSAN

Biopharmaceutical company developing a novel formulation of zolmitriptan administered via proprietary intracutaneous microneedle patch delivery system
- Year Invested
  2018
- Fund
  IV
- Sector
  Biopharma
- Company Status
  public
- Investment Status
  current
- Location
  Fremont, CA
- Website
  zosanopharma.com

Portfolio

Portfolio Companies

Aclaris Therapeutics, Inc.

Year Invested

Fund

Sector

Company Status

Investment Status

Location

Website

Adams Respiratory Therapeutics, Inc.

Year Invested

Fund

Sector

Company Status

Investment Status

Location

Website

ADMA Biologics, Inc.

Year Invested

Fund

Sector

Company Status

Investment Status

Location

Website

Advion, Inc.

Year Invested

Fund

Sector

Company Status

Investment Status

Location

Website

Agile Therapeutics, Inc.

Year Invested

Fund

Sector

Company Status

Investment Status

Location

Website

Aimmune Therapeutics, Inc.

Year Invested

Fund

Sector

Company Status

Investment Status

Location

Website

Ajax Health

Year Invested

Fund

Sector

Company Status

Investment Status

Location

Website

Allos Therapeutics, Inc.

Year Invested

Fund

Sector

Company Status

Investment Status

Location

Website

Ambit Biosciences Corporation

Year Invested

Fund

Sector

Company Status

Investment Status

Location

Website

Aragon Pharmaceuticals, Inc.

Year Invested

Fund

Sector

Company Status

Investment Status